{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:48:23Z","timestamp":1759366103410,"version":"build-2065373602"},"reference-count":35,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BeOne Medicines Ltd."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2025,8,24]]},"DOI":"10.1080\/10428194.2025.2506501","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T08:28:00Z","timestamp":1747988880000},"page":"1884-1892","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"66","author":[{"given":"Vincent","family":"L\u00e9vy","sequence":"first","affiliation":[{"name":"Clinical Research D\u00e9partement, H\u00f4pital Avicenne, AP-HP et Universit\u00e9 Sorbonne Paris Nord","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tushar","family":"Srivastava","sequence":"additional","affiliation":[{"name":"ConnectHEOR","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raju","family":"Gautam","sequence":"additional","affiliation":[{"name":"ConnectHEOR","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpi","family":"Swami","sequence":"additional","affiliation":[{"name":"ConnectHEOR","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaijun","family":"Wang","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd. USA","place":["San Mateo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd. USA","place":["San Mateo, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyla","family":"Mohseninejad","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd, Netherlands B.V","place":["Schiphol, the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0239-8"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.06.003"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.840616"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-1039-y"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06791.x"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2856"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1784120"},{"key":"e_1_3_3_10_1","unstructured":"CMS. Medicare drug price negotiation program: negotiated prices for initial price applicability year 2026; 2024. https:\/\/www.cms.gov\/files\/document\/fact-sheet-negotiated-prices-initial-price-applicability-year-2026.pdf"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00756-9"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1946"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2262378"},{"key":"e_1_3_3_15_1","unstructured":"Brukinsa\u00ae (zanubrutinib). US FDA Prescribing information. 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213217s007lbl.pdf"},{"key":"e_1_3_3_16_1","unstructured":"Brukinsa (zanubrutinib). European Medicines Agency. EPAR - medicine overview; 2022. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/brukinsa-epar-medicine-overview_en.pdf"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1772"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.1.36"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-005-1579-7"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2018.1434414"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3595"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.202"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147112"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.04.001"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-826008"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44228-022-00015-5"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44228-022-00020-8"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_3_29_1","unstructured":"European Medicines Agency. Revised framework of EMA interaction with patients consumers and their organisations; 2014. https:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-revised-framework-european-medicines-agency-interaction-patients-consumers-and-their-organisations-isabelle-moulon_en.pdf"},{"key":"e_1_3_3_30_1","unstructured":"European Medicines Agency. Engagement framework: european Medicines Agency and patients consumers and their organisations; 2022. https:\/\/www.ema.europa.eu\/en\/documents\/other\/engagement-framework-european-medicines-agency-and-patients-consumers-and-their-organisations_en.pdf"},{"key":"e_1_3_3_31_1","unstructured":"US Food and Drug Administration. Plan for issuance of patient-focused drug development guidance under 21st Century Cures Act Title III Section 3002. 2017. https:\/\/www.fda.gov\/files\/about%20fda\/published\/Plan-for-Issuance-of-Patient%E2%80%90Focused-Drug-Development-Guidance.pdf"},{"key":"e_1_3_3_32_1","unstructured":"US Food Drug Administration. Patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making; 2025. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw258"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.332"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0257"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6706"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2025.2506501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:06:32Z","timestamp":1759273592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2025.2506501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8,24]]}},"alternative-id":["10.1080\/10428194.2025.2506501"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2025.2506501","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"type":"print","value":"1042-8194"},{"type":"electronic","value":"1029-2403"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}